BIIB
Price
$132.22
Change
-$0.43 (-0.32%)
Updated
Aug 29 closing price
Capitalization
19.39B
51 days until earnings call
PFE
Price
$24.76
Change
+$0.16 (+0.65%)
Updated
Aug 29 closing price
Capitalization
140.77B
64 days until earnings call
Interact to see
Advertisement

BIIB vs PFE

Header iconBIIB vs PFE Comparison
Open Charts BIIB vs PFEBanner chart's image
Biogen
Price$132.22
Change-$0.43 (-0.32%)
Volume$1.08M
Capitalization19.39B
Pfizer
Price$24.76
Change+$0.16 (+0.65%)
Volume$37.03M
Capitalization140.77B
BIIB vs PFE Comparison Chart in %
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIIB vs. PFE commentary
Sep 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a StrongBuy and PFE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 01, 2025
Stock price -- (BIIB: $132.22 vs. PFE: $24.76)
Brand notoriety: BIIB and PFE are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 79% vs. PFE: 91%
Market capitalization -- BIIB: $19.39B vs. PFE: $140.77B
BIIB [@Pharmaceuticals: Major] is valued at $19.39B. PFE’s [@Pharmaceuticals: Major] market capitalization is $140.77B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $656.73B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $89.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • PFE’s FA Score: 1 green, 4 red.
According to our system of comparison, PFE is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 5 TA indicator(s) are bullish while PFE’s TA Score has 7 bullish TA indicator(s).

  • BIIB’s TA Score: 5 bullish, 4 bearish.
  • PFE’s TA Score: 7 bullish, 4 bearish.
According to our system of comparison, PFE is a better buy in the short-term than BIIB.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а -5.09% price change this week, while PFE (@Pharmaceuticals: Major) price change was -4.33% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.73%. For the same industry, the average monthly price growth was +1.44%, and the average quarterly price growth was +12.21%.

Reported Earning Dates

BIIB is expected to report earnings on Oct 22, 2025.

PFE is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.73% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PFE($141B) has a higher market cap than BIIB($19.4B). PFE (13.10) and BIIB (12.65) have similar P/E ratio . PFE YTD gains are higher at: -1.651 vs. BIIB (-13.536). PFE has higher annual earnings (EBITDA): 20.2B vs. BIIB (2.79B). PFE has more cash in the bank: 13.2B vs. BIIB (2.76B). BIIB has less debt than PFE: BIIB (6.6B) vs PFE (60.9B). PFE has higher revenues than BIIB: PFE (63.8B) vs BIIB (10B).
BIIBPFEBIIB / PFE
Capitalization19.4B141B14%
EBITDA2.79B20.2B14%
Gain YTD-13.536-1.651820%
P/E Ratio12.6513.1097%
Revenue10B63.8B16%
Total Cash2.76B13.2B21%
Total Debt6.6B60.9B11%
FUNDAMENTALS RATINGS
BIIB vs PFE: Fundamental Ratings
BIIB
PFE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
7361
PRICE GROWTH RATING
1..100
6155
P/E GROWTH RATING
1..100
9597
SEASONALITY SCORE
1..100
5042

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PFE's Valuation (4) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (89) in the Biotechnology industry. This means that PFE’s stock grew significantly faster than BIIB’s over the last 12 months.

PFE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as BIIB (100) in the Biotechnology industry. This means that PFE’s stock grew similarly to BIIB’s over the last 12 months.

PFE's SMR Rating (61) in the Pharmaceuticals Major industry is in the same range as BIIB (73) in the Biotechnology industry. This means that PFE’s stock grew similarly to BIIB’s over the last 12 months.

PFE's Price Growth Rating (55) in the Pharmaceuticals Major industry is in the same range as BIIB (61) in the Biotechnology industry. This means that PFE’s stock grew similarly to BIIB’s over the last 12 months.

BIIB's P/E Growth Rating (95) in the Biotechnology industry is in the same range as PFE (97) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to PFE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBPFE
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
59%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
58%
Bullish Trend 4 days ago
51%
Momentum
ODDS (%)
Bearish Trend 4 days ago
69%
Bearish Trend 4 days ago
60%
MACD
ODDS (%)
Bearish Trend 4 days ago
70%
Bearish Trend 4 days ago
64%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
70%
Bearish Trend 4 days ago
60%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
57%
Bullish Trend 4 days ago
54%
Advances
ODDS (%)
Bullish Trend 11 days ago
53%
Bullish Trend 11 days ago
57%
Declines
ODDS (%)
Bearish Trend 4 days ago
69%
Bearish Trend 7 days ago
59%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
72%
Bullish Trend 4 days ago
60%
Aroon
ODDS (%)
Bullish Trend 4 days ago
57%
Bullish Trend 4 days ago
54%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HARD30.770.48
+1.57%
Simplify Commodities Strategy No K-1 ETF
LDRC25.330.01
+0.05%
iShares iBonds 1-5 Year Corporate Ladder ETF
KAPR33.74-0.05
-0.14%
Innovator Russell 2000 Pwr Bffr ETF Apr
HNDL21.85-0.09
-0.39%
Strategy Shares Nasdaq 7 Handl™ ETF
SPMO116.48-1.32
-1.12%
Invesco S&P 500® Momentum ETF